

Half-Year Ended 31 December 2020

Justin Walter – Chief Executive Officer & Managing Director Craig Bremner – Chief Financial Officer

23 February 2021

CAPITOLHEALTH

TABLE OF CONTENTS

01. Highlights

02. Financials

03. Growth

04. Appendix

05. Disclaimer





HY21 Highlights

Key Achievements and Highlights:

- Revenue increase of \$4.7m (5.9%) to \$85.3m
- COVID-19 impacts in Victoria successfully managed
- Operating EBITDA increased by 50.1% to \$26.6m
- Statutory NPAT up 131.6% to \$6.2m
- Management focus on sustained market share growth gaining traction
- Strategic plan implementation driving operating margin expansion
- Operating Margin of 31.1% up from 22.0% (ex JobKeeper 24.3%)
- All clinical roles maintained through the pandemic lockdown with Jobkeeper assistance, providing essential services to referrers and patients
- Announced acquisition of Direct Radiology
- Fowler Simmons Acquisition integrated and delivering on expectations
- Interim dividend for FY21 declared at 0.5 cents per share fully franked
- · New Camberwell site opened

Strategic plan milestones:

- Patient experience now continually measured via net promoter scores and surveys
- E-referral implemented nationally
- Head of Growth appointed
- Annual staff survey and employee value proposition in place
- Branding and digital marketing plan defined and underway
- National Clinical Governance Framework implemented
- Chief Medical Officer appointed
- New national telephony system rollout underway to improve incoming call management and patient / referrer experience

HY21 RESULTS SUMMARY

REVENUE

\$85.3m

Up 5.9% pcp

OPERATING EBITDA

\$26.6m

Up 50.1% pcp

OPERATING EBITDA MARGIN

31.1%

Up from 22.0% pcp

FREE CASH FLOW

\$16.7m

Up 148.4% pcp

NET DEBT / OPERATING EBITDA*

0.1x


*calculated excluding adoption of AASB 16 Lease adjustments

INTERIM DPS


0.5 cps

Fully franked

INDUSTRY GROWTH BELOW LONG TERM TREND



- Rolling 12 month growth rates for DI Revenues and Services experienced a steep decline during the nationwide lockdown between March and May 2020 and was further impacted by the second Victorian lockdown that commenced in July 2020
- A strong recovery was observed in December 2020
- DI revenues are increasing due to additional MRI licenses in FY20 (prior to Covid-19) and MBS indexation of certain items from July 2020




- GP attendances have returned to long-term averages prior to COVID-19 of above 6% assisted by telehealth services
- Demand for DI services in Victoria has also bounced back in December 2020 post easing of lockdown restrictions.

¹ – Data included in each graph is inclusive of only the states in which Capitol Health operates in (VIC, TAS, WA, SA) Source: Medicare Australia Statistics - http://medicarestatistics.humanservices.gov.au/statistics/mbs_group.jsp



A STRONG AND DEFENSIVE SOURCE OF REVENUE



- Capitol's community clinic sites and bulk billing revenue stream remains a robust and defensive income source
- Out of pocket revenue increasing at a higher rate due to subtle changes in the service mix
- Fowler Simmons acquired in March 2020, has a higher ratio of out of pocket (OOP) revenue due to specialist diagnostic services



HY21 – OPERATING RESULTS

Operating EBITDA reconciliation				
\$000	HY21	HY20	Change	% Change
Revenue	85,305	80,554	4,751	5.9%
Wages, Contractor Costs, Salaries	(45,685)	(49,796)	4,111	8.3%
Other Operating Costs	(13,067)	(13,065)	(2)	0.0%
Operating EBITDA	26,554	17,693	8,861	50.1%
Operating EBITDA Margin	31.1%	22.0%	9.2%	41.7%
Revaluation/(impairment) of financial assets	(2,416)	-	(2,416)	n/m
Transaction and restructure costs	(1,490)	(1,676)	186	11.1%
Profit before Finance Costs, Depreciation and Amortisation and Income Tax	22,648	16,017	6,631	41.4%

- Revenue of \$85.3m is up \$4.7m or 5.9% over pcp
- Wages, Contractor Costs and Salaries reduced by \$4.1m or 8.3% on pcp
- · Operating margin expansion due to systematic cost and operational review
- Other Operating Costs held flat to pcp
- Operating EBITDA of \$26.6m, an increase of \$8.9m or 50.1% on pcp
- Operating EBITDA margin increases to 31.1% (ex JobKeeper 24.3%), up from 22.0% pcp
- Impairment adjustment relates to the impact of the foreign exchange rate movement to the fair value of Enlitic investment over the six month period (AUD:USD)

HY21 – CASH FLOW

Cash Flow Summary			
\$000	HY21	HY20	% Change
Cash receipts	85,470	81,575	,
Cash payments	(56,031)	(65,337)	
Net Interest	(1,676)	(1,780)	
Income tax paid	(3,620)	59	
Net Cash from operations	24,143	14,517	66.3%
Cash flows from Investing Activities			
Payments of Capex	(3,782)	(5,330)	
Payments for Business Acquisitions	(1,579)	(8,008)	
Net Cash from Investing Activities	(5,361)	(13,338)	(59.8%)
Cash flows from Financing Activities			
Proceeds from Conversion of Share Options	197	-	
Payment of Dividends	(8,997)	(3,842)	
Payments of dividends to non-controlling interests	(92)		
Net proceeds on Issue/(Buy Back) Share Capital	-	(10)	
Proceeds of Borrowings	-	5,000	
Payments for leasing arrangements	(4,605)	(4,176)	
Net Cash from Financing Activities	(13,497)	(3,028)	345.7%
Net increase/(decrease) in Cash and equivalents	5,285	(1,849)	
Cash at Beginning	13,763	7,330	
Cash at End	19,048	5,481	247.5%

Other Key Cash Measures			
\$000	HY21	HY20	% Change
Net Cash from Operations	24,143	14,517	66.3%
Maintenance CAPEX	(2,863)	(3,629)	(21.1%)
Lease payments	(4,605)	(4,176)	10.3%
Free Cash Flow	16,675	6,712	148.4%
FCF/Operating EBITDA	62.8%	37.9%	

- Generated free cash flow of \$16.7m up 148.4% pcp
- Improved free cash flow conversion on operating EBITDA of 62.8%
 up from 37.9% in pcp
- Maintenance CAPEX investment down slightly due to COVID-19 constraints and improved asset allocation methodologies

CAPITAL MANAGEMENT









Funding for Growth

- Strong balance sheet
- \$132.5m of unused Facilities
- Net debt \$2.9m (excl. AASB 16 Leases)
- Gearing at 0.1 times operating EBITDA (prior to AASB16) provides significant headroom for growth, particularly acquisitions

Data Driven Approach

- Making considered capital management decisions based on the best use of capital and shareholder returns, with reference to:
- Company strategy
- Market outlook
- Opportunity cost of a range of growth alternatives
- · Return on investment
- Positive EPS Impact

Share Buy Back

- No share buy-back in HY21 as the business identifies greater returns for capital
- The company refreshed its buy-back capacity in August 2019, allowing a further 76.8m shares to be acquired
- The company continues its commitment to buying back shares when the share price is not reflective of value

Dividends

- Declared an interim dividend for HY21 of 0.5 cents per share
- The company continues its commitment to a sustainable fully franked dividend

HY21 – CAPEX INVESTMENT

- Maintenance CAPEX investment approach has been reviewed to ensure that Capitol is optimising asset utilisation, reflecting revenue growth and required replacement levels to avoid capital sensitivity impacts
- Expansion/growth CAPEX slightly lower than anticipated due to COVID -19 constraints with key projects due in 2HFY21
- Camberwell site opened October 20
- · Depreciation & Amortisation consistent with prior period

CAPEX		
****	113/04	111/00
\$000	HY21	HY20
Maintenance	2,863	3,629
Growth	919	1,701
Total	3,782	5,330
Depreciation & Amortisation	(10,070)	(9,970)





4 ENGINES OF GROWTH









Organic

- During FY20 we undertook a review of the cost base and where we could improve efficiencies. This approach continued to deliver in HY21
- We successfully matched patient demand to our resourcing during lockdown 1.0 & Vic 2.0
- In FY21 we are focused on market share and the 'go to' market strategy for organic growth

Clinic Expansion and Upgrades

We continue to review and optimise our network of clinics.

There are three prongs to this approach:

- 1. Open Greenfield Clinics
- 2. Brownfield redevelopment and upgrading of modalities
- 3. Clinic portfolio review of profitability

Acquisitions

- Location that complements our network
- 2. Alignment with our Company Vision, Values and Strategy
- 3. Where clinic investment will drive organic growth
- 4. To obtain access to people and systems
- 5. Where synergies have been identified
- Pricing makes sense and will deliver value to shareholders.

Technology Investment

- New employee engagement software
- Communications and data centre strategy
- Datawarehouse created with new BI Tool
- Referrer interface software and telehealth functionality
- Unlisted investment in Enlitic a leading Al software developer in Radiology

MAKING PROGRESS FOR FUTURE ORGANIC GROWTH

Key Growth Drivers



Market demand for services recovering strongly in December, driven by fundamentals of macro drivers



Strong bounce back following Victorian second wave, demonstrates the resilience of demand



Focus continues on the existing business and the development of a rolling bolt on acquisition and Greenfield/Brownfield pipeline to continue momentum and growth



Building on our commitment to patients, staff activity will more closely align with patient demand – measured in real-time through investment in new systems



Regular 'cost-to-serve' reviews improving efficiencies at a day-to-day level



Our portfolio approach to clinic review will ensure appropriate community coverage and diagnostic modalities



Continue to build the BDM function and go to market approach with a customer value proposition



Data driven decision making with BI, pulling together data from 10 operational sources



Medicare DI indexation introduced in July 2020 – approx 1.5% average across 60% of CAJ item codes

Outlook

- Focus on continuing to deliver both revenue and operating EBITDA organic growth
- Investment in the front end of our business in operations systems and communications optimization
- Standard operating model implementation to catalyse scalability
- Continuing to improve the 'cost-to-serve' of the business
- Carry a strong balance sheet during the period of uncertainty due to the Covid-19 pandemic while investing in well defined growth opportunities
- Well positioned to continue to pursue value-creative acquisitions






THE CAPITOL BUSINESS

Overview

- Capitol is an ASX-listed provider of diagnostic imaging and related services to the Australian healthcare market. We are a talented team of experts motivated by our patients' needs
- We own and operate 63 clinics throughout VIC, SA, TAS and WA, with a growth focus aided by our scalable operating model
- As a community focused company, our facilities are predominantly suburban rather than hospitalbased, with priority given to service and minimisation of administrative burdens for healthcare professionals
- We meet a growing consumer demand and conduct more than 1.2 million procedures every year, employing ~800 staff and ~100 radiologists
- Our significant market position means we can adapt to changing industry dynamics and make strategic investments





Our Vision:

To be the diagnostic imaging specialists of choice, serving our communities with compassion, integrity and precision



No. 1 in patient satisfaction



Our Aspirations:



Leading team satisfaction & retention rate



Sustained marketshare growth



Industry-leading shareholder returns

Our Values:

Patient centred

We create positive patient experiences. We listen with respect, inform with empathy and involve patients in their care

One Team

Our people are our best asset. Our outcomes are better when we work together. We treat each other with respect and nurture a culture of recognition, empathy and inclusion

Integrity

We are open and honest. We take pride in the way we work. Our patients and partners trust us because we are accountable and reliable

Excellence

Together we pursue excellence – in outcomes and experience for our patients, referrers and community. We utilise the best technology to deliver timely, precise results

Community focused

We are more than a network, we are a community. We create meaningful connections with our patients, referrers and colleagues built on trust, support and shared goals

The Pillars of our Business:

Operational Excellence

- Standardised operating model as platform for organic growth
- Value creation through postacquisition integration
- Performance management through business intelligence and analytics

Destination Employer

- Employee Value Proposition
- Clear performance & reward mechanisms
- · Focus on professional development
- Values driven people processes

Next-generation Technology

- Highly secure and effective technology model
- Holistic approach to technology encompassing clinical outcomes, operational efficiency and patient experience

First-choice Provider

- Differentiated customer and marketing plan
- Focus on and resourcing referrer relationship management including CRM implementation
- Patient experience management

Values-based Communications

- Coherent stakeholder communications strategy
- Focus on developing industry and government relationships
- · Industry thought leadership program



CAPITOL STRATEGIC PILLARS



First Choice Provider

- We aim to be the first choice for community-based diagnostic imaging
- Our strategies are based on qualitative and quantitative research into patient and referrer behaviour and preferences. The insights we gather inform our approach, and constant optimisation of the patient / referrer experience
- We build strong relationships with our referrers, providing them with precise and timely diagnostic imaging



Destination Employer

- We recruit, develop and retain the best clinical, technical and corporate staff; we recognise staff for their service and values
- We're implementing a feedback and coaching framework, and clearly defined remuneration strategy, to increase staff satisfaction / competency and reduce costs
- We're focused on our people and building a strong culture supported by our values. We seek feedback from staff on a regular basis and respond to insights accordingly



Next-generation Technology

- We're committed to the strategic implementation of next-generation technology to enhance service, quality and engagement
- We will deploy unified RIS platforms to improve service quality, load sharing and efficiency in existing and growth business units
- We will implement optimal online booking, eReferral, eForms and Pt Kiosk platform
- To support radiologists and deliver efficient reporting we will implement smart worklists
- We embrace Al in our business through strategic partnerships such as Enlitic



Operational Excellence

- Optimising operational efficiencies and clinical outcomes (e.g. timeliness, quality, standard processes) at a reduced cost-to-serve, through:
 - Evidence-based standard operating model (SOM)
 - Focused workflow management to maximise efficiency and quality
 - Benchmark human resource allocation and asset utilisation



Values-based Communications

- We're strengthening our brand, and building our reputation through strategic, valuescentric communications, by:
 - Clearly and consistently communicating our business vision, purpose and CVPs
 - Identifying and nurturing strategic experience relationships
 - Demonstrating communitycentred values and experiences
 - Communicating the 'why' to key stakeholders with clear, accurate messaging
 - Demonstrating good corporate citizenship



HY21 – STRONG BALANCE SHEET

\$000	31 Dec 2020	30 Jun 2020
Current Assets		
Cash and Cash Equivalents	19,048	13,763
Trade and Other Receivables	4,606	5,493
Other Financial Assets	262	277
Other Assets	1,540	767
Total Current Assets	25,456	20,300
Non-Current Assets		
Plant & Equipment	40,159	40,820
Right-of-Use Asset	57,656	54,729
Intangible Assets	117,358	117,949
Other Financial Assets	19,722	22,138
Other Receivables	362	630
Deferred Tax Asset	5,510	5,741
Total Non-Current Assets	240,767	242,007
Total Assets	266,223	262,307
Current Liabilities		
Trade and Other Payables	14,666	16,967
Loans and Borrowings	- 1,000	-
Lease Liabilities	9,406	9,640
Employee Benefit Liabilities	11,729	10,828
Income Tax Liability	3,922	2,751
Total Current Liabilities	39,723	40,186
Non-Current Liabilities		
Borrowings	17,000	17,000
Lease Liabilities	55,796	52,702
Other Financial Liabilities	4,884	3,698
Provisions	1,340	1,340
Employee Benefit	817	852
Deferred Tax Liabilities	2,030	2,490
Total Non-Current Liabilities	81,867	78,082
Total Liabilities	121,590	118,268
Net Assets	144,633	144,039

• Strong balance sheet highly supportive of growth and acquisition opportunities







DISCLAIMER

This presentation is the property of Capitol Health Limited (Capitol). This presentation is not and does not constitute an offer, invitation or recommendation to subscribe for, or purchase any security and neither this presentation nor anything contained in it shall form the basis of any contract or commitment.

This presentation does not constitute an offer or invitation in any jurisdiction anywhere, or to any person to whom, such an offer would be unlawful. This presentation is not intended as an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in the United States or to any person to whom it is unlawful to make such an offer or solicitation. The securities that may be included in any offering have not been, and will not be registered under the US Securities Act.

Reliance should not be placed on the information or opinions contained in this presentation. This presentation does not take into consideration the investment objectives, financial situation or particular needs of any particular investor. Any decision to

purchase or subscribe for securities in Capitol must be made solely on the basis of the information contained in the in the public domain and if necessary, after seeking appropriate financial advice.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, Capitol and its affiliates and related bodies corporate, and their respective officers, directors, employees and agents disclaim any liability (including, without limitation, any liability arising from fault or negligence) for any loss arising from any use of this presentation (or its content) or otherwise arising in connection with it.

Capitol's forward-looking statements, intentions, forecasts, prospects, returns, expectations, statements in relation to future matters or other forward looking statement contained in this presentation may involve significant elements of subjective judgement and assumptions as to future events which may or may not

be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. They are based on a number of estimates, assumptions that are subject to business, scientific, economic and competitive uncertainties and contingencies, with respect to future business decisions, which are subject to change and, in many cases, are outside the control of Capitol and its directors. Neither Capitol nor its directors give any assurance that the forecast performance in the forecasts or any forward-looking statement contained in this presentation will be achieved.